Lutein and Alzheimer's Disease Study (LAD)

Oregon Health & Science University (OHSU)

Status and phase: Terminated; Phase 2

Conditions: Alzheimer's Disease

Treatments: Dietary Supplement: placebo; Dietary Supplement: lutein/zeaxanthin

Study type: Interventional

Funder types: Other

Identifiers

NCT00596024

Alzheimer research fund

LAD

Details and patient eligibility

About

Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxidants that have important functions for human health. Carotenoids are known to reduce oxidative damage, but their effects have not been studied in AD patients.

The objective of the study is to examine whether lutein supplementation helps to reduce oxidative damage from free radicals in AD patients.

Enrollment: 3 patients

Sex: All

Ages: 55+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosed with moderately severe Alzheimer's disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

3 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

Daily Lutein/zeaxanthin supplementation with a meal

Treatment:

Dietary Supplement: lutein/zeaxanthin

2

Placebo Comparator group

Treatment:

Dietary Supplement: placebo